Aevitas Wealth Management, Inc. Crispr Therapeutics Ag Transaction History

Aevitas Wealth Management, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 19, 2022	SELL	$70.09 - $111.29 $307,484 - $488,229	-4,387 Closed	0 $0
Q3 2021 Nov 01, 2021	BUY	$110.2 - $156.64 $11,020 - $15,663	100 Added 2.33%	4,387 $491,000
Q2 2021 Jul 22, 2021	BUY	$100.84 - $161.89 $30,252 - $48,566	300 Added 7.52%	4,287 $694,000
Q1 2021 Apr 29, 2021	BUY	$110.72 - $210.04 $26,572 - $50,409	240 Added 6.41%	3,987 $486,000
Q4 2020 Jan 19, 2021	BUY	$79.67 - $173.23 $298,523 - $649,092	3,747 New	3,747 $574,000
Q2 2019 Jul 26, 2019	SELL	$35.45 - $48.2 $82,137 - $111,679	-2,317 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$22.73 - $42.34 $34,095 - $63,510	-1,500 Reduced 39.3%	2,317 $66,000
Q3 2018 Nov 14, 2018	SELL	$44.35 - $65.71 $221,750 - $328,549	-5,000 Reduced 56.71%	3,817 $169,000
Q2 2018 Aug 10, 2018	BUY	$42.62 - $73.59 $84,004 - $145,045	1,971 Added 28.79%	8,817 $518,000
Q1 2018 May 15, 2018	SELL	$23.52 - $58.17 $511,442 - $1.26 Million	-21,745 Reduced 76.06%	6,846 $313,000
Q4 2017 Feb 13, 2018	BUY	$16.95 - $23.48 $484,617 - $671,316	28,591	28,591 $671,000

489

57.9M

1.09M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.16B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Aevitas Wealth Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Aevitas Wealth Management, Inc. with notifications on news.